|
1
|
Oliveira C, Pinheiro H, Figueiredo J,
Seruca R and Carneiro F: Familial gastric cancer: Genetic
susceptibility, pathology, and implications for management. Lancet
Oncol. 16:e60–e70. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000-14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Goetze OT, Al-Batran SE, Chevallay M and
Mönig SP: Multimodal treatment in locally advanced gastric cancer.
Updates Surg. 70:173–179. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bi J, Bai Z, Ma X, Song J, Guo Y, Zhao J,
Yi X, Han S and Zhang Z: Txr1: An important factor in oxaliplatin
resistance in gastric cancer. Med Oncol. 31(807)2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Peng B, Chen Y and Leong KW: MicroRNA
delivery for regenerative medicine. Adv Drug Deliv Rev. 88:108–122.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
El Bezawy R, Cominetti D, Fenderico N,
Zuco V, Beretta GL, Dugo M, Arrighetti N, Stucchi C, Rancati T,
Valdagni R, et al: miR-875-5p counteracts epithelial-to-mesenchymal
transition and enhances radiation response in prostate cancer
through repression of the EGFR-ZEB1 axis. Cancer Lett. 395:53–62.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qiu X and Dou Y: miR-1307 promotes the
proliferation of prostate cancer by targeting FOXO3A. Biomed
Pharmacother. 88:430–435. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhu DY, Li XN, Qi Y, Liu DL, Yang Y, Zhao
J, Zhang CY, Wu K and Zhao S: MiR-454 promotes the progression of
human non-small cell lung cancer and directly targets PTEN. Biomed
Pharmacother. 81:79–85. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fang B, Zhu J, Wang Y, Geng F and Li G:
MiR-454 inhibited cell proliferation of human glioblastoma cells by
suppressing PDK1 expression. Biomed Pharmacother. 75:148–152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun L, Wang QL, Gao XC, Shi DJ, Mi SY and
Han Q: MicroRNA-454 functions as an oncogene by regulating PTEN in
uveal melanoma. FEBS Lett. 589:2791–2796. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yu L, Gong XJ, Sun L, Yao H, Lu BL and Zhu
LY: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene exression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee HK, Finniss S, Cazacu S, Bucris E,
Ziv-Av A, Xiang C, Bobbitt K, Rempel SA, Hasselbach L, Mikkelsen T,
et al: Mesenchymal stem cells deliver synthetic microRNA mimics to
glioma cells and glioma stem cells and inhibit their cell migration
and self-renewal. Oncotarget. 4:346–361. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yu X, Li Z and Liu J: MiRNAs in primary
cutaneous lymphomas. Cell Prolif. 48:271–277. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wu X, Ding N, Hu WT, He J, Xu S, Pei H,
Hua J, Zhou G and Wang J: Down-regulation of BTG1 by miR-454-3p
enhances cellular radiosensitivity in renal carcinoma cells.
Radiation Oncol. 9(179)2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang DH, Wang GY, Zhang JW, Li Y, Zeng XC
and Jiang N: MiR-501-5p regulates CYLD expression and promotes cell
proliferation in human hepatocellular carcinoma. Jpn J Clin Oncol.
45:738–744. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Massoumi R: CYLD: A deubiquitination
enzyme with multiple roles in cancer. Future Oncol. 7:285–297.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gautheron J and Luedde T: A novel player
in inflammation and cancer: The deubiquitinase CYLD controls HCC
development. J Hepatol. 57:937–939. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nikolaou K, Tsagaratou A, Eftychi C,
Kollias G, Mosialos G and Talianidis I: Inactivation of the
deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation,
fibrosis, and cancer. Cancer Cell. 21:738–750. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu G, Zhu H, Zhang M and Xu J: Histone
deacetylase 3 is associated with gastric cancer cell growth via the
miR-454-mediated targeting of CHD5. Int J Mol Med. 41:155–163.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Masoumi KC, Shaw-Hallgren G and Massoumi
R: Tumor suppressor function of CYLD in nonmelanoma skin cancer. J
Skin Cancer. 2011(614097)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Orfanidou T, Xanthopoulos K, Dafou D,
Pseftogas A, Hadweh P, Psyllaki C, Hatzivassiliou E and Mosialos G:
Down-regulation of the tumor suppressor CYLD enhances the
transformed phenotype of human breast cancer cells. Anticancer Res.
37:3493–3503. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yan YF, Gong FM, Wang BS and Zheng W:
MiR-425-5p promotes tumor progression via modulation of CYLD in
gastric cancer. Eur Rev Med Pharmacol Sci. 21:2130–2136.
2017.PubMed/NCBI
|
|
27
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W and Wang T: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Niu J and Mims MP: Oxaliplatin-induced
thrombotic thrombocytopenic purpura: Case report and literature
review. J Clin Oncol. 30:E312–E314. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tsimberidou AM, Said R, Culotta K, Wistuba
I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, et
al: Phase I study of azacitidine and oxaliplatin in patients with
advanced cancers that have relapsed or are refractory to any
platinum therapy. Clin Epigenetics. 7(29)2015.PubMed/NCBI View Article : Google Scholar
|
